News

2017

DATE

TITLE

November 16 The Effects of ProtoKinetix' Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to Immunotherapy
October 17 Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery
June 5 ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP™ in Immune Cell Cryopreservation Testing
May 24 ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP™
Mar 9 ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP™ PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes
Feb 7 ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration
Jan 24 ProtoKinetix Announces Investigator Sponsored Human Clinical Trial Application Using AAGP™ Has Been Approved by Health Canada
Jan 17 ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP™ in the Treatment of Type 1 Diabetes
   

 

2016

DATE

TITLE

July 14 ProtoKinetix’ 2nd Quarter Scientific Update
June 16 ProtoKinetix Completes Non-Brokered Private Placement & Secures Operating Line of Credit
June 7 ProtoKinetix’ AAGP™ has been Published in the Journal of Tissue Engineering and Regenerative Medicine
May 12 ProtoKinetix Updates Progress Toward Clinical Trial Application for AAGP™
May 2 AAGP™ Improves Results in Stem Cells Transplanted in Retina Tissue by 300%
April 26 ProtoKinetix Outlines Steps to Clinical Trial Application for AAGP™